NASDAQ:APTX - Aptinyx Stock Price, Forecast & News

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

Aptinyx Inc (NASDAQ:APTX) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.44) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.44). The company earned $0.94 million during the quarter, compared to analyst estimates of $0.91 million. Aptinyx had a negative return on equity of 44.24% and a negative net margin of 1,523.09%. View Aptinyx's Earnings History.

Aptinyx is scheduled to release their next quarterly earnings announcement on Thursday, March 19th 2020. View Earnings Estimates for Aptinyx.

6 equities research analysts have issued 12 month price targets for Aptinyx's shares. Their forecasts range from $7.00 to $12.00. On average, they anticipate Aptinyx's share price to reach $10.33 in the next year. This suggests a possible upside of 186.2% from the stock's current price. View Analyst Price Targets for Aptinyx.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptinyx.

Headlines about APTX stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aptinyx earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Aptinyx.

Aptinyx saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 192,200 shares, an increase of 13.4% from the January 15th total of 169,500 shares. Based on an average daily trading volume, of 240,200 shares, the short-interest ratio is presently 0.8 days. Approximately 0.9% of the shares of the stock are short sold. View Aptinyx's Current Options Chain.

Some companies that are related to Aptinyx include Basilea Pharmaceutica (BPMUF), Urogen Pharma (URGN), Flexion Therapeutics (FLXN), BioXcel Therapeutics (BTAI), Molecular Templates (MTEM), Clovis Oncology (CLVS), ZIOPHARM Oncology (ZIOP), XBiotech (XBIT), Crinetics Pharmaceuticals (CRNX), TherapeuticsMD (TXMD), Ardelyx (ARDX), AC Immune (ACIU), MacroGenics (MGNX), Kura Oncology (KURA) and Axovant Sciences (AXON).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), Opko Health (OPK), VBI Vaccines (VBIV), vTv Therapeutics (VTVT), Canopy Growth (CGC), Kadmon (KDMN), Inovio Pharmaceuticals (INO), Strongbridge Biopharma (SBBP), SCYNEXIS (SCYX) and Abeona Therapeutics (ABEO).

(APTX) raised $77 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Aptinyx's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Farallon Capital Management LLC (0.93%), Renaissance Technologies LLC (0.70%), Jacobs Levy Equity Management Inc. (0.43%), Oxford Asset Management LLP (0.40%), Marshall Wace LLP (0.33%) and Acadian Asset Management LLC (0.26%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach and Torsten M Madsen. View Institutional Ownership Trends for Aptinyx.

APTX stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Marshall Wace LLP, Oxford Asset Management LLP, Russell Investments Group Ltd., Alambic Investment Management L.P. and Goldman Sachs Group Inc.. View Insider Buying and Selling for Aptinyx.

APTX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Jacobs Levy Equity Management Inc., DCF Advisers LLC, Spark Investment Management LLC and Acadian Asset Management LLC. Company insiders that have bought Aptinyx stock in the last two years include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach and Torsten M Madsen. View Insider Buying and Selling for Aptinyx.

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of APTX stock can currently be purchased for approximately $3.61.

Aptinyx has a market capitalization of $158.30 million and generates $6.57 million in revenue each year. The company earns $-53,280,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. View Additional Information About Aptinyx.

The official website for Aptinyx is http://www.aptinyx.com/.

Aptinyx's mailing address is 1801 MAPLE AVENUE SUITE 4300, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]